Skip to content

Board of Directors

The Evox Board of directors is comprised of highly accomplished advisors who each contribute significant expertise in their respective fields. They provide support and guidance to the management team of Evox in achieving its bold vision to positively impact human health by creating novel exosome-based biotherapeutics.

Paul Carter

Non-Executive Chairman

Paul is a widely respected leader and Board member where he has over the last 25 years held a variety of senior commercial leadership roles in the bio-pharmaceutical industry, formally serving as Executive Vice President, Chief Commercial Officer at Gilead Sciences. He currently serves on the Board of several listed and private pharmaceutical companies.

Dr Antonin de Fougerolles

Chief Executive Officer and Director

Tony has over 20 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities towards the market and in helping build several multi-billion dollar companies from start-up stage including Moderna, Alnylam, and Ablynx.

Chau Q Khuong

Non-Executive Director

Chau is Partner at OrbiMed Advisors and since 2003 has principally focused on Venture Capital investments. Over his investment career, Chau has extensive experience in financing research and development of new medicines and therapeutic devices at all stages, across different drug modalities, and a range of disease areas from oncology to infectious diseases to ophthalmology.

John McHutchison

Non-Executive Director

John is an experienced life sciences executive who is currently Chief Executive Officer and President of Assembly Biosciences. Prior to this, he spent nine years at Gilead Sciences as Chief Scientific Officer and Head of Research & Development.

Amrit Nagpal

Non-Executive Director

Amrit is a Managing Director, Private Investments at Redmile Group, LLC, a healthcare-focused investment firm based in San Francisco and New York.

Martin Andrews

Non-Executive Director

Martin is a respected commercial leader with a strong track record in strategy development and operational delivery most recently as Senior Vice President, Rare Diseases at GlaxoSmithKline, where he oversaw the development and launch of Strimvelis, the world’s first life-saving gene therapy for children. He currently serves on the Board of Freeline Therapeutics.

Sarah Gordon Wild

Non-Executive Director

Sarah has worked on Wall Street for over 15 years and was Managing Director, Management Committee Member and Senior Healthcare Analyst at Lone Pine Capital LLC from 1998 to 2003. She is also currently on the board of Oxford Nanopore and Redx

Professor Matthew Wood

Board Observer

Matthew is Professor of Neuroscience and Deputy Head of the Medical Sciences Division at Oxford University and directs the Laboratory of RNA Biology and Neuromuscular Disease.

Kevin Raidy

Board Observer

Kevin Raidy is the Managing Partner of Cowen Healthcare Investments. He is currently a member of the Board of Directors for several biotechnology companies including Aro Biotherapeutics and Orchard Therapeutics.

Vidu Shanmugarajah

Board Observer

Vidu is a partner on the investing team at GV, based in London. He is also GV’s legal counsel for Europe. Before joining GV in 2015, Vidu’s career spanned law, startups, and investing.